VITRAKVI\u00ae is the commercial brand name of Larotrectinib Sulfate Capsules, a highly selective tropomyosin receptor kinase (TRK) inhibitor developed by Bayer. It exerts anti-tumor activity by specifically inhibiting the kinase activity of tropomyosin receptor kinases (TRKA, TRKB, TRKC) encoded by NTRK gene fusions, thereby blocking downstream signaling pathways and suppressing the proliferation and survival of tumor cells harboring these fusions.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy VITRAKVI (Larotrectinib Sulfate Capsules)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":" VITRAKVI\u00ae is the commercial brand name of Larotrectinib Sulfate Capsules, a highly selective tropomyosin receptor kinase (TRK) inhibitor developed by Bayer. It exerts anti-tumor activity by specifically inhibiting the kinase activity of tropomyosin receptor kinases (TRKA, TRKB, TRKC) encoded by NTRK gene fusions, thereby blocking downstream signaling pathways and suppressing the proliferation and survival of […]<\/p>\n","protected":false},"author":4,"featured_media":3295,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, who have metastatic disease or are likely to progress following surgery, and who have no satisfactory alternative treatments or whose disease progressed following prior treatment.<\/p>\n\n\n\n
Common adverse reactions: Fatigue, nausea, dizziness, vomiting, anemia, constipation, diarrhea, cough, peripheral edema, and abdominal pain.
Laboratory abnormalities: Decreased neutrophil count, decreased lymphocyte count, decreased hemoglobin, and increased transaminases.
Severe but manageable risks: Central nervous system adverse reactions (including dizziness, cognitive impairment, and mood disorders), hepatotoxicity, and skeletal fractures.<\/p>\n\n\n\n
VITRAKVI\u00ae (Larotrectinib Sulfate Capsules, 100mg) was officially approved for marketing in China in April 2022. It is currently a prescription drug included in China\u2019s Category B medical insurance.<\/p>\n\n\n\n